Evaluation of the safety and efficacy of T-AYU-HM Premium and Onion steam inhalation in mild to moderate Covid-19 Patients
Clinical trial study
Abstract
Coronavirus disease (COVID-19) has impacted many nations' health care and their economic growth within no time. This Pandemic situation demands a safe and cost-effective treatment as early as possible to prevent any further suffering. To clinically evaluate the safety and efficacy of T-AYU-HM Premium Tablets (600 mg) and onion steam inhalation in mild to moderate COVID-19 patients. The trial is an open-label, Single-arm study conducted in mild to moderate level coronavirus patients. 30 participants infected by the coronavirus enrolled for the study, on providing informed consent. AYUSH standard mark anti-sickling tablet T-AYU-HM Premium 600mg twice a day and onion steam inhalation once every morning once for 21 days was prescribed to the patients along with strict home quarantine instructions. Both clinical and pathological changes recorded on the baseline, 5th, and 21st day of the trial. Any adverse events reported by the patients and those observed by the principal investigator recorded. All the patients recovered clinically, and no untoward effects observed during this trial period. A significant reduction (p < 0.05) observed in the pathological parameters like C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and lactate dehydrogenase (LDH). The oxygen saturation (SpO2) level sustained within normal limits during the treatment period suggesting that further complications and hospitalization evaded. The impact of the treatment regimen T-AYU-HM Premium and onion steam inhalation on clinical and pathological parameters suggest that it is safe and indicate its potential candidacy in the treatment of COVID-19.
Keywords:
Coronavirus, T-AYU-HM Premium, Onion steam inhalation, CRP, ESR,LDHDOI
https://doi.org/10.25004/IJPSDR.2022.140212References
Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2021 Apr 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32150360.
Rascon-Castelo E,Burgara-Estrella A, Mateu E, et al. Immunological features of the non-structural proteins of porcine reproductive and respiratory syndrome virus. Viruses. 2015; 7(3):873-886. doi:10.3390/v7030873
Turner AJ. ACE2 Cell Biology, Regulation, and Physiological Functions. The Protective Arm of the Renin Angiotensin System (RAS). 2015; 185-189. doi:10.1016/B978-0-12-801364-9.00025-0
Ruan Q,Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5):846-848. doi: 10.1007/ s00134-020-05991-x.
Ang L,Song E, Lee HW, et al. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2020; 9(5):1583.doi:10.3390/jcm9051583
Sanchez M,Lodi F, Vera R,et al. Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J Nutr. 2007; 137(4):910-5. doi: 10.1093/jn/137.4.910.
Wilson, E.A. and Demmig Adams B. Antioxidant, anti-inflammatory, and antimicrobial properties of garlic and onions; Nutrition & Food Science 2007, Vol. 37 No. 3, pp. 178-183. https://doi. org/10.1108/00346650710749071
Chen L,Li J, Luo C, et al. Binding interaction of quercetin-3- beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features. Bioorg Med Chem. 2006 Dec 15;14(24):8295-306. doi: 10.1016/j.bmc.2006.09.014. Epub 2006 Oct 12. PMID: 17046271; PMCID: PMC7125754.
Chiang LC, Chiang W, Liu MC, et al. In vitro antiviral activities of Caesalpiniapulcherrima and its related flavonoids. J Antimicrob Chemother. 2003; 52(2):194-8. doi: 10.1093/jac/dkg291.
Vessal M, Hemmati M, Vasei M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp BiochemPhysiol C ToxicolPharmacol. 2003 Jul; 135C (3):357-64. doi: 10.1016/s1532- 0456(03)00140-6.
Paradkar HS, editor. Ch. 20, Ver. 5. Varanasi: ChowkhambaKrishnadas Academy; 2006. AshtangHridaya of Vagbhata, Sutra Sthana; NasyavidhiAdhyaya. Reprint Edition; p. 287.
Desai AM,Saraf MN, Desai C,et al. Clinical evaluation of T-AYU-HMTM in the management of sickle cell anemia. Int J Pharm Sci & Res 2018; 9(8): 3573-78. doi: 10.13040/IJPSR.0975-8232.9(8).3573-78.
Wei-jie Guan,Zheng-yi Ni, Yu Hu, et al. Clinical characteristics of 2019 novel corona virus infection in China. medRxiv 2020;10.110 1/2020.02.06.20020974
Tang N,Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel corona virus pneumonia. J ThrombHaemost.2020; 18(4):844–847. doi: 10.1111/ jth.14768.
Desai A, Desai K, Desai H, et al. A Case Report on the Effects of Onion Steam Vapour/Nebulisation and T-AYU-HM Premium Tablets in COVID-19 Patient. J Pharm Sci Bioscientific Res. 2020.10(2):171-174
Rothan, H. A. & Byrareddy, S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity vol. 109 102433 (2020).
Singh V, Rana RK, Singhal R. Analysis of repeated measurement data in the clinical trials. J Ayurveda Integr Med. 2013; 4(2):77-81. doi:10.4103/0975-9476.113872
Evans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010;3(1):8-18. doi:10.6030/1939-067x-3.1.8
K. Cheng,M. Wei, H. Shen, etal.Clinical characteristics of 463 patients with common and severe type coronavirus disease (In Chinese) Shanghai Med J (2020), pp. 1-15
P. Mehta, D.F. McAuley, M. Brown, et al.COVID-19: consider cytokine storm syndromes and immunosuppression; Lancet, 395 (10229) (2020), pp. 1033-1034
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020; 75:2352–2371. doi: 10.1016/j.jacc.2020.03.031
Drent M,Cobben N, Henderson R,et al. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996; 9: 1736–42.
Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995; 108: 415–18.
Lu A,Wang C, Zhang X, et al. Lactate dehydrogenase as a biomarker for prediction of refractory mycoplasma pneumoniae pneumonia in children. Respir Care 2015; 60: 1469–75.
Tishkowski K, Gupta V. Erythrocyte Sedimentation Rate. [Updated 2020 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www. ncbi.nlm.nih.gov/books/NBK557485/
Chung S, Kim JE, Park S, et al. Neutrophil and monocyte activation markers have prognostic impact in disseminated intravascular coagulation: in vitro effect of thrombin on monocyte CD163 shedding. Thromb Res. 2011;127(5):450–6
Wagner J, DuPont A, Larson S, et al. Absolute lymphocyte count is a prognostic marker in COVID-19: A retrospective cohort review. Int J Lab Hematol. 2020; 42(6):761-765. doi:10.1111/ijlh.13288
Published
Abstract Display: 412 
PDF Downloads: 423 
